Engineered CD8+ cytotoxic T cells with fiber-modified adenovirus-mediated TNF-α gene transfection counteract immunosuppressive interleukin-10-secreting lung metastasis and solid tumors

Cancer Gene Therapy

Volumn 14, Issue 7, 2007, Pages 661-675

  Ye, Z ^a,b   Shi, M ^a,b   Chan, T ^a,b   Sas, S ^a,b   Xu, S ^a,b   Xiang, J ^a,b  

^a SASKATCHEWAN CANCER AGENCY   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Cytotoxicity; Engineering; IL 10; Survival; T cell therapy; TNF

Indexed keywords

ADENOVIRUS VECTOR; ARGINYLGLYCYLASPARTIC ACID; CD8 ANTIGEN; INTERLEUKIN 10; OVALBUMIN; PLASMID DNA; PLASMID DNA INTERLEUKIN 10; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ARTICLE; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; DNA MODIFICATION; GENE INSERTION; GENE VECTOR; GENETIC ENGINEERING; GENETIC TRANSFECTION; HOST CELL; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; LUNG METASTASIS; MELANOMA; MELANOMA CELL; MEMORY T LYMPHOCYTE; MICROMETASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; TRANSGENE; TUMOR IMMUNITY;

ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOSUPPRESSION; INTERLEUKIN-10; LUNG NEOPLASMS; MELANOMA; MICE; MICE, TRANSGENIC; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; THYMOMA; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA;

ADENOVIRIDAE; MUS;

EID: 34250365239     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/sj.cgt.7701039     Document Type: Article

References (65)

1. Plautz GE, Touhalisky JE, Shu S. Treatment of murine gliomas by adoptive transfer of ex vivo activated tumor-draining lymph node cells. Cell Immunol 1997; 178: 101-107.
2. Peng L, Shu S, Krauss JC. Treatment of subcutaneous tumor with adoptively transferred T cells. Cell Immunol 1997; 178: 24-32.
3. Tanaka H, Yoshizawa H, Yamaguchi Y, Ito K, Kagamu H, Suzuki E et al. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells. J Immunol 1999; 162: 3574-3582.
4. Eck SC, Turka LA. Adoptive transfer enables tumor rejection targeted against a self-antigen without the induction of autoimmunity. Cancer Res 2001; 61: 3077-3083.
5. Dobrzanski MJ, Reome JB, Dutton RW. Type 1 and type 2 CD8+ effector T cell subpopulations promote long-term tumor immunity and protection to progressively growing tumor. J Immunol 2000; 164: 916-925.
6. Becker C, Pohla H, Frankenberger B, Schuler T, Assenmacher M, Schendel DJ et al. Adoptive tumor therapy with T lymphocytes enriched through an IFN-gamma capture assay. Nat Med 2001; 7: 1159-1162.
7. Gastl GA, Abrams JS, Nanus DM, Oosterkamp R, Silver J, Liu F et al. Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression. Int J Cancer 1993; 55: 96-101.
8. Smith DR, Kunkel SL, Burdick MD, Wilke CA, Orringer MB, Whyte RI et al. Production of interleukin-10 by human bronchogenic carcinoma. Am J Pathol 1994; 145: 18-25.
9. Taga K, Mostowski H, Tosato G. Human interleukin-10 can directly inhibit T-cell growth. Blood 1993; 81: 2964-2971.
10. Steinbrink K, Graulich E, Kubsch S, Knop J, Enk AH. CD4(+) and CD8(+) anergic T cells induced by interleukin-10-treated human dendritic cells display antigen-specific suppressor activity. Blood 2002; 99: 2468-2476.
11. Groux H, Bigler M, de Vries JE, Roncarolo MG. Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells. J Exp Med 1996; 184: 19-29.
12. Hsieh CL, Chen DS, Hwang LH. Tumor-induced immunosuppression: a barrier to immunotherapy of large tumors by cytokine-secreting tumor vaccine. Hum Gene Ther 2000; 11: 681-692.
13. Hara M, Kingsley CI, Niimi M, Read S, Turvey SE, Bushell AR et al. IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo. J Immunol 2001; 166: 3789-3796.
14. Yang AS, Lattime EC. Tumor-induced interleukin 10 suppresses the ability of splenic dendritic cells to stimulate CD4 and CD8 T-cell responses. Cancer Res 2003; 63: 2150-2157.
15. Kawamura K, Bahar R, Natsume W, Sakiyama S, Tagawa M. Secretion of interleukin-10 from murine colon carcinoma cells suppresses systemic antitumor immunity and impairs protective immunity induced against the tumors. Cancer Gene Ther 2002; 9: 109-115.
16. Garcia-Hernandez ML, Hernandez-Pando R, Gariglio P, Berumen J. Interleukin-10 promotes B16-melanoma growth by inhibition of macrophage functions and induction of tumour and vascular cell proliferation. Immunology 2002; 105: 231-243.
17. Chau GY, Wu CW, Lui WY, Chang TJ, Kao HL, Wu LH et al. Serum interleukin-10 but not interleukin-6 is related to clinical outcome in patients with resectable hepatocellular carcinoma. Ann Surg 2000; 231: 552-558.
18. De Vita F, Orditura M, Galizia G, Romano C, Lieto E, Iodice P et al. Serum interleukin-10 is an independent prognostic factor in advanced solid tumors. Oncol Rep 2000; 7: 357-361.
19. Robinet E, Branellec D, Termijtelen AM, Blay JY, Gay F, Chouaib S et al. Evidence for tumor necrosis factor-alpha involvement in the optimal induction of class I allospecific cytotoxic T cells. J Immunol 1990; 144: 4555-4561.
20. Lahn M, Kalataradi H, Mittelstadt P, Pflum E, Vollmer M, Cady C et al. Early preferential stimulation of gamma delta T cells by TNF-alpha. J Immunol 1998; 160: 5221-5230.
21. Zhang W, Chen Z, Li F, Kamencic H, Juurlink B, Gordon JR et al. Tumour necrosis factor-alpha (TNF-alpha) transgene-expressing dendritic cells (DCs) undergo augmented cellular maturation and induce more robust T-cell activation and anti-tumour immunity than DCs generated in recombinant TNF-alpha. Immunology 2003; 108: 177-188.
22. Lyakh LA, Koski GK, Telford W, Gress RE, Cohen PA, Rice NR et al. Bacterial lipopolysaccharide, TNF-alpha, and calcium ionophore under serum-free conditions promote rapid dendritic cell-like differentiation in CD14+ monocytes through distinct pathways that activate NK-kappa B. J Immunol 2000; 165: 3647-3655.
23. Sepulveda H, Cerwenka A, Morgan T, Dutton RW. CD28, IL-2-independent costimulatory pathways for CD8 T lymphocyte activation. J Immunol 1999; 163: 1133-1142.
24. Brunner C, Seiderer J, Schlamp A, Bidlingmaier M, Eigler A, Haimerl W et al. Enhanced dendritic cell maturation by TNF-alpha or cytidine-phosphate-guanosine DNA drives T cell activation in vitro and therapeutic anti-tumor immune responses in vivo. J Immunol 2000; 165: 6278-6286.
25. Brossart P, Zobywalski A, Grunebach F, Behnke L, Stuhler G, Reichardt VL et al. Tumor necrosis factor alpha and CD40 ligand antagonize the inhibitory effects of interleukin 10 on T-cell stimulatory capacity of dendritic cells. Cancer Res 2000; 60: 4485-4492.
26. Wright P, Braun R, Babiuk L, Littel-van den Hurk SD, Moyana T, Zheng C et al. Adenovirus-mediated TNF-alpha gene transfer induces significant tumor regression in mice. Cancer Biother Radiopharm 1999; 14: 49-57.
27. Xiang J, Huang H, Liu Y. A new dynamic model of CD8+ T effector cell responses via CD4+ T helper-antigen-presenting cells. J Immunol 2005; 174: 7497-7505.
28. Li M, Davey GM, Sutherland RM, Kurts C, Lew AM, Hirst C et al. Cell-associated ovalbumin is cross-presented much more efficiently than soluble ovalbumin in vivo. J Immunol 2001; 166: 6099-6103.
29. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B et al. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 1998; 95: 2509-2514.
30. Liu Y, Ye T, Sun D, Maynard J, Deisseroth A. Conditionally replication-competent adenoviral vectors with enhanced infectivity for use in gene therapy of melanoma. Hum Gene Ther 2004; 15: 637-647.
31. Chan T, Sami A, El-Gayed A, Guo X, Xiang J. HER-2/neu-gene engineered dendritic cell vaccine stimulates stronger HER-2/neu-specific immune responses compared to DNA vaccination. Gene ther 2006; 13: 1391-1402.
32. Zeng M, Smith SK, Siegel F, Shi Z, Van Kampen KR, Elmets CA et al. AdEasy system made easier by selecting the viral backbone plasmid preceding homologous recombination. Biotechniques 2001; 31: 260-262.
33. Huang H, Liu Y, Xiang J. Synergistic effect of adoptive T-cell therapy and intratumoral interferon gamma-inducible protein-10 transgene expression in treatment of established tumors. Cell Immunol 2002; 217: 12-22.
34. Chen Z, Huang H, Chang T, Carsen S, Saxena A, Marr R et al. Enhanced HER-2/neu-specific antitumor immunity by cotransduction of mouse dendritic cells with two genes encoding HER-2/neu and alpha tumor necrosis factor. Cancer Gene Ther 2002; 9: 778-786.
35. Liu Y, Huang H, Chen Z, Zong L, Xiang J. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity. J Gene Med 2003; 5: 668-680.
36. Xia D, Hao S, Xiang J. CD8+ cytotoxic T-APC stimulate central memory CD8+ T cell responses via acquired peptide-MHC class I complexes and CD80 costimulation and IL-2 secretion. J Immunol 2006; 177: 2976-2984.
37. Speiser DE, Romero P. Toward improved immunocompetence of adoptively transferred CD8+ T cells. J Clin Invest 2005; 115: 1467-1469.
38. Zammit DJ, Cauley LS, Pham QM, Lefrancois L. Dendritic cells maximize the memory CD8 T cell response to infection. Immunity 2005; 22: 561-570.
39. Dyer MR, Herrling PL. Progress and potential for genebased medicines. Mol Ther 2000; 1: 213-224.
40. Marshall E. Gene therapy. Second child in French trial is found to have leukemia. Science 2003; 299: 320.
41. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997; 275: 1320-1323.
42. Wickham TJ, Mathias P, Cheresh DA, Nemerow GR. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 1993; 73: 309-319.
43. Nemerow GR. Cell receptors involved in adenovirus entry. Virology 2000; 274: 1-4.
44. Huang S, Endo RI, Nemerow GR. Upregulation of integrins alpha v beta 3 and alpha v beta 5 on human monocytes and T lymphocytes facilitates adenovirus-mediated gene delivery. J Virol 1995; 69: 2257-2263.
45. Huang S, Kamata T, Takada Y, Ruggeri ZM, Nemerow GR. Adenovirus interaction with distinct integrins mediates separate events in cell entry and gene delivery to hematopoietic cells. J Virol 1996; 70: 4502-4508.
46. Okada N, Saito T, Masunaga Y, Tsukada Y, Nakagama S, Mizuguchi H et al. Efficient antigen gene transduction using Arg-Gly-Asp fiber-mutant adenovirus vectors can potentiate antitumor vaccine efficacy and maturation of murine dendritic cells. Cancer Res 2001; 61: 7913-7919.
47. Okada N, Masunaga Y, Okada Y, Iiyama S, Mori N, Tsuda T et al. Gene transduction efficiency and maturation status in mouse bone marrow-derived dendritic cells infected with conventional or RGD fiber-mutant adenovirus vectors. Cancer Gene Ther 2003; 10: 421-431.
48. Kagi D, Vignaux F, Ledermann B, Burki K, Depraetere V, Nagata S et al. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 1994; 265: 528-530.
49. Huang H, Li F, Gordon JR, Xiang J. Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression. Cancer Res 2002; 62: 2043-2051.
50. Huang H, Bi XG, Yuan JY, Xu SL, Guo XL, Xiang J. Combined CD4+ Th1 effect and lymphotactin transgene expression enhance CD8+ Tc1 tumor localization and therapy. Gene Ther 2005; 12: 999-1010.
51. Winter H, Hu HM, Urba WJ, Fox BA. Tumor regression after adoptive transfer of effector T cells is independent of perforin or Fas ligand (APO-1L/CD95L). J Immunol 1999; 163: 4462-4472.
52. Poehlein CH, Hu HM, Yamada J, Assmann I, Alvord WG, Urba WJ et al. TNF plays an essential role in tumor regression after adoptive transfer of perforin/IFN-gamma double knockout effector T cells. J Immunol 2003; 170: 2004-2013.
53. Hollenbaugh JA, Dutton RW. IFN-gamma regulates donor CD8 T cell expansion, migration, and leads to apoptosis of cells of a solid tumor. J Immunol 2006; 177: 3004-3011.
54. Blohm U, Potthoff D, van der Kogel AJ, Pircher H. Solid tumors 'melt' from the inside after successful CD8 T cell attack. Eur J Immunol 2006; 36: 468-477.
55. Prevost-Blondel A, Roth E, Rosenthal FM, Pircher H. Crucial role of TNF-alpha in CD8 T cell-mediated elimination of 3LL-A9 Lewis lung carcinoma cells in vivo. J Immunol 2000; 164: 3645-3651.
56. Sarraf C. Tumor necrosis factor and cell death in tumors. Int J Oncol 1994; 5: 1333-1339.
57. Tracey KJ, Cerami A. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu Rev Med 1994; 45: 491-503.
58. Ruegg C, Yilmaz A, Bieler G, Bamat J, Chaubert P, Lejeune FJ et al. Evidence for the involvement of endothelial cell integrin alpha V beta 3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat Med 1998; 4: 408-414.
59. Denekamp J. Review article: angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol 1993; 66: 181-196.
60. Valencia X, Stephens G, Goldbach-Mansky R, Wilson M, Shevach EM, Lipsky PE. TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood 2006; 108: 253-261.
61. Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995; 333: 1038-1044.
62. Dudley ME, Wunderlich J, Nishimura MI, Yu D, Yang JC, Topalian SL et al. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother 2001; 24: 363-373.
63. Sprent J, Tough DF. T cell death and memory. Science 2001; 293: 245-248.
64. Zhang HG, Liu C, Su K, Yu S, Zhang L, Zhang S et al. A membrane form of TNF-alpha presented by exosomes delays T cell activation-induced cell death. J Immunol 2006; 176: 7385-7393.
65. Dobrzanski MJ, Reome JB, Hollenbaugh JA, Dutton RW. Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses. J Immunol 2004; 172: 1380-1390.